Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Industry Incentives Out Of DSHEA Purview - Pharmanex Brief

This article was originally published in The Tan Sheet

Executive Summary

Protection of research incentives for prescription drug manufacturers was not an objective of Congress when it drafted the Dietary Supplement Health & Education Act, Pharmanex contends in an Aug. 23 brief to the Salt Lake City federal court. The argument was submitted by the Cholestin marketer in response to FDA's July 20 brief for appeal.
Advertisement

Related Content

Pharmanex v. Shalala
Pharmanex v. Shalala
Pharmanex v. Shalala
Cholestin Decision Threat To "Pioneer" Drug Exclusivity Cited In FDA Appeal
Pharmanex seeking court order to allow red yeast rice imports.
Pharmanex seeking court order to allow red yeast rice imports.

Topics

Advertisement
UsernamePublicRestriction

Register

PS090275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel